Eric A. Collisson

15.8k total citations · 3 hit papers
81 papers, 5.2k citations indexed

About

Eric A. Collisson is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Eric A. Collisson has authored 81 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 36 papers in Cancer Research and 30 papers in Molecular Biology. Recurrent topics in Eric A. Collisson's work include Pancreatic and Hepatic Oncology Research (34 papers), Cancer Genomics and Diagnostics (33 papers) and Melanoma and MAPK Pathways (9 papers). Eric A. Collisson is often cited by papers focused on Pancreatic and Hepatic Oncology Research (34 papers), Cancer Genomics and Diagnostics (33 papers) and Melanoma and MAPK Pathways (9 papers). Eric A. Collisson collaborates with scholars based in United States, Denmark and Switzerland. Eric A. Collisson's co-authors include Joe W. Gray, Adam B. Olshen, William J. Gibb, Douglas Hanahan, Anguraj Sadanandam, Andrew H. Ko, Margaret A. Tempero, Paul T. Spellman, Shenda Gu and Morgan Truitt and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature Communications.

In The Last Decade

Eric A. Collisson

77 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

2011 1.2k citations Eric A. Collisson, Shenda Gu et al. profile →
A colorectal cancer classification system that associates cellular phenotype and responses to therapy

2013 721 citations Eric A. Collisson, Adam B. Olshen et al. profile →
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

2015 470 citations Oliver A. Zill, Dragan Sebisanovic et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric A. Collisson United States	30	2.9k	2.2k	2.1k	1.0k	689	81	5.2k
Salvatore Piscuoglio Switzerland	39	1.7k 0.6×	2.5k 1.1×	2.7k 1.3×	1.0k 1.0×	567 0.8×	133	5.3k
Michael J. Pishvaian United States	40	3.8k 1.3×	1.9k 0.9×	1.5k 0.7×	1.1k 1.1×	747 1.1×	216	5.8k
Charlotte K.Y. Ng Switzerland	42	2.6k 0.9×	2.4k 1.1×	3.5k 1.7×	1.5k 1.5×	668 1.0×	120	6.5k
Nilofer S. Azad United States	41	3.8k 1.3×	2.3k 1.0×	1.3k 0.6×	1.4k 1.3×	1.1k 1.6×	205	6.3k
Élena Elez Spain	38	4.5k 1.5×	1.7k 0.8×	1.2k 0.6×	1.4k 1.3×	951 1.4×	212	6.1k
David S. Rickman United States	34	1.4k 0.5×	2.8k 1.3×	1.6k 0.8×	1.6k 1.6×	706 1.0×	63	5.6k
David S. Shames United States	45	2.9k 1.0×	3.0k 1.3×	1.9k 0.9×	2.4k 2.4×	421 0.6×	110	6.1k
Katsuya Tsuchihara Japan	38	2.1k 0.7×	2.9k 1.3×	1.6k 0.7×	1.3k 1.3×	309 0.4×	148	5.1k
Gorana Tomasic France	33	4.4k 1.5×	1.7k 0.8×	1.3k 0.6×	1.4k 1.4×	689 1.0×	63	6.0k
Aaron Pollett Canada	33	3.9k 1.3×	2.6k 1.2×	1.7k 0.8×	633 0.6×	710 1.0×	87	6.8k

Countries citing papers authored by Eric A. Collisson

Since Specialization

Citations

This map shows the geographic impact of Eric A. Collisson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric A. Collisson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric A. Collisson more than expected).

Fields of papers citing papers by Eric A. Collisson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric A. Collisson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric A. Collisson. The network helps show where Eric A. Collisson may publish in the future.

Co-authorship network of co-authors of Eric A. Collisson

This figure shows the co-authorship network connecting the top 25 collaborators of Eric A. Collisson. A scholar is included among the top collaborators of Eric A. Collisson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric A. Collisson. Eric A. Collisson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Linossi, Edmond M., J. N. K. Rao, Christian B. Macdonald, et al.. (2025). Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning. eLife. 13. 1 indexed citations

Linossi, Edmond M., J. N. K. Rao, Christian B. Macdonald, et al.. (2024). Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning. eLife. 13. 3 indexed citations

Linossi, Edmond M., Christian B. Macdonald, Jennifer M. Michaud, et al.. (2023). Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain. eLife. 12. 6 indexed citations

Ozen, Mehmet Ozgün, Eva Hrabeta‐Robinson, Amit K. Behera, et al.. (2022). Mutant KRAS regulates transposable element RNA and innate immunity via KRAB zinc-finger genes. Cell Reports. 40(3). 111104–111104. 8 indexed citations

Muir, Ryan K., Adam B. Olshen, Iwei Yeh, et al.. (2021). Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS -driven tumors. The Journal of Experimental Medicine. 219(4). 16 indexed citations

Linossi, Edmond M., et al.. (2021). State of the structure address on MET receptor activation by HGF. Biochemical Society Transactions. 49(2). 645–661. 11 indexed citations

Walker, Evan J., Dena Goldberg, Julia Carnevale, et al.. (2021). Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. The Oncologist. 26(11). e1982–e1991. 23 indexed citations

Wang, Yung-Hua, Jeremy Sharib, Junnian Wei, et al.. (2020). Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer. Clinical Cancer Research. 26(14). 3608–3615. 27 indexed citations

Montesion, Meagan, Thomas Botton, Eric A. Collisson, et al.. (2018). Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion. The Oncologist. 23(9). 998–1003. 3 indexed citations

10.

Lu, Xinyuan, Nir Peled, John J. Greer, et al.. (2017). MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma. Cancer Research. 77(16). 4498–4505. 49 indexed citations

11.

Premasekharan, Gayatri, Elizabeth Gilbert, Ross A. Okimoto, et al.. (2016). An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Letters. 380(1). 144–152. 21 indexed citations

12.

Ko, Andrew H., Tanios Bekaii‐Saab, Jessica Van Ziffle, et al.. (2015). A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research. 22(1). 61–68. 100 indexed citations

13.

Zill, Oliver A., Claire Greene, Dragan Sebisanovic, et al.. (2015). Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discovery. 5(10). 1040–1048. 202 indexed citations

14.

Lin, Luping, Saurabh Asthana, Elton Chan, et al.. (2014). Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proceedings of the National Academy of Sciences. 111(7). E748–57. 73 indexed citations

15.

Mirzoeva, Olga K., Eric A. Collisson, Peter M. Schaefer, et al.. (2013). Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma. Molecular Cancer Therapeutics. 12(10). 2213–2225. 34 indexed citations

16.

Trejo, Christy L., Shon Green, Victoria Marsh, et al.. (2013). Mutationally Activated PIK3CAH1047R Cooperates with BRAFV600E to Promote Lung Cancer Progression. Cancer Research. 73(21). 6448–6461. 33 indexed citations

17.

Griffith, Obi L., François Pépin, Oana M. Enache, et al.. (2013). A robust prognostic signature for hormone-positive node-negative breast cancer. Genome Medicine. 5(10). 92–92. 15 indexed citations

18.

Collisson, Eric A., Christy L. Trejo, Jillian M. Silva, et al.. (2012). A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma. Cancer Discovery. 2(8). 685–693. 219 indexed citations

19.

Collisson, Eric A., et al.. (2002). Isoprenylation is Necessary for the Full Invasive Potential of RhoA Overexpression in Human Melanoma Cells. Journal of Investigative Dermatology. 119(5). 1172–1176. 29 indexed citations

20.

Collisson, Eric A., Hamid Nourmand, Christopher B. Cooper, et al.. (2002). Retrospective analysis of the results of liver transplantation for adults with severe hepatopulmonary syndrome. Liver Transplantation. 8(10). 925–931. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact